Down 4.5% today, more than its biotech peers' 1.4%; no story names it yet.
Rose 24% since Nov 4
Up 24% from Nov 4 to Nov 10.
Follow EWTX's trial news. Pro members can get an alert when Edgewise Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| The chart | Stronger than 93% of stocks |
| Latest filing | 8-K, Nov 4 |
TodayNo story names it yet.
Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.
1 more date ahead: the conference, for Pro members.
After its last 4 reports it closed -0.8% on average, higher 1 of 4 times.
About 1 quarter
CMO Joanne M. Donovan sold 9,441 shares on Aug 13. 10 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
Well above its recent run. EWTX scores 10 today, against a median of 4 over its last 20 recorded sessions.
EWTX is #50 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 50 |
Net income over four quarters: EWTX $1.01B, ELVN -$113M.
Expected to report Thu Feb 25, after the close (in 107 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A profit of $9.65 a share, from a loss of $0.39.
“The increase was primarily attributable to higher personnel - related costs, including stock - based”
EWTX's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“$1,166.2 million, or $10.71 per basic share and $9.65 per diluted share, for the third quarter of 2026, compared to a net loss and net loss per share of $40.7 million, or $0.39 per basic and diluted share, for the same period in 2025, primarily reflecting the gain recognized on the sale of sevasemten to Servier, partially offset by income tax expense associated with the transaction.”
From its results filing (SEC filing · Nov 4)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 4, 2026 | +14.6% | +3.6% | not yet |
| Aug 6, 2026 | -1.9% | -1.3% | -3.2% |
| May 7, 2026 | +2.7% | -3.8% | -8.7% |
RSI 65.8, MACD above signal, above both averages. Not scored.
6 insiders sold $2.1M across 20 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: EWTX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
EWTX scores 10 today, which Breakaway calls Average. It is #50 of 281 in Biotech by Quality Score, with 4 of 14 chart checks firing. Up 24% from Nov 4 to Nov 10. Cash lasts about 1 quarter at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
EWTX scores 10 today, which Breakaway calls Average (6 to 10). That is #50 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind EWTX's 10.
6 insiders sold $2.1M across 20 filings in the last 6 months. No open-market buys on record. The newest is Michael Nofi, Chief Financial Officer, who sold $202K on Nov 10. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.